New Chiral Stationary Phase

该项目的总体目标是开发新的、高性能的手性分离固定相。这些相是由约50摩尔%交联剂和50摩尔%手性选择剂组成的共聚物。它们是基于Fenris Technology Research， Inc.开发的新型共聚物相。这些新材料已经证明了在反相模式下与二氧化硅基相相当的色谱效率，甚至更好地用于苯胺的正常相分离。它们结合了高效和高容量的手性分离。第一阶段的目标是确认新的手性固定相的预期优势。手性选择剂将是脯氨酸-芳香胺缀合物，已被证明具有高的手性选择性。新阶段的性能将与现有的商业阶段进行比较。关键的实验将是测量对映体的分辨率作为在新相和商业相上注入相同溶质的外消旋物的量的函数。第一阶段的可行性将通过展示新的手性固定相可以分离至少两倍的外消旋体，并且具有令人满意的分辨率，与同等尺寸和粒度的竞争商业柱相比。建议的商业应用：分离和分离光学纯异构体。这对涉及对映体药物的制药工业极为重要。光纯药物是有效的，没有其他对映体的副作用。

The overall goal of this project is to develop new, high performance stationary phases for chiral separations. These phases are copolymers consisting of approximately 50 mole-% crosslinker and 50 mole-% chiral selectors. They are based on new co-polymer phases developed by Fenris Technology Research, Inc. These new materials have demonstrated chromatographic efficiencies that are equivalent to silica based phases in the reversed phase mode and even better for the normal phase separation of aniline. They will combine high efficiency and high capacity for chiral separations. The Phase I goal is to confirm the expected advantages of new chiral stationary phase. The chiral selector will be a proline-aromatic amine conjugate that has been demonstrated to provide high chiral selectivity. The performance of the new phase will be compared to existing commercial phases. The key experiment will be to measure enantiomer resolution as a function of he amount of injected racemate for the same solute on both the new phase and commercial phases. Phase I feasibility will be established by showing the new chiral stationary phase can separate at least twice as much racemate with satisfactory resolution as competing commercial columns of equivalent dimensions and particle size. PROPOSED COMMERCIAL APPLICATIONS: Separation and isolation of optically pure isomers. This is extremely important to the pharmaceutical industry where enantiomeric drugs are involved. Optically pure drugs are effective without the side effects of the other enantiomer.